SUTRO BIOPHARMA, INC.

STRO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016
Operating Activities
Net Income $-19.7M $1.7M
Depreciation & Amortization $5.0M $5.7M
Depreciation
Amortization
Stock-Based Compensation $1.4M $968.0K
Net Cash from Operating Activities $-37.1M $-13.2M
Investing Activities
Capital Expenditures $3.3M $4.4M
Business Acquisitions
Net Cash from Investing Activities $32.6M $9.6M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $14.6M $177.0K
Net Change in Cash $10.2M $-3.4M
Free Cash Flow $-40.4M $-17.5M
← Newer Page 2 of 2 Older →